Article
Hematology
Krischan Braitsch, Alix Schwarz, Katrin Koch, Mara Hubbuch, Helge Menzel, Ulrich Keller, Katharina S. Goetze, Florian Bassermann, Peter Herhaus, Mareike Verbeek
Summary: This retrospective analysis compares the efficacy and tolerability of reduced intensity conditioning regimens, Flu/Treo and FLAMSA-RIC, in patients with myeloid malignancies undergoing alloSCT. The results indicate that there is no significant difference in engraftment, survival, relapse, transplant-related mortality, and graft-versus-host disease between the two regimens.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Cheonghwa Lee, Ha Nui Kim, Jung Ah Kwon, Jinha Hwang, Ji-Ye Park, Ok Sarah Shin, Soo-Young Yoon, Jung Yoon
Summary: Complex karyotype (CK) is associated with poor prognosis in AML and MDS-EB, and dysregulated gene expression may be involved. We identified a 10-gene signature (CKS) that accurately predicts CK and is associated with shorter overall survival.
Article
Hematology
Olga K. Weinberg, Alexa Siddon, Yazan F. Madanat, Jeffrey Gagan, Daniel A. Arber, Paola Dal Cin, Damodaran Narayanan, Madhu M. Ouseph, Jason H. Kurzer, Robert P. Hasserjian
Summary: This study evaluated the clinicopathologic features and outcomes of AML and MDS patients with complex karyotype (CK). The presence of TP53 mutation, especially multihit TP53 mutation, in the context of CK, identified a homogeneously aggressive disease, irrespective of blast count or therapy-relatedness.
Article
Biophysics
Xavier Poire, Myriam Labopin, Emmanuelle Polge, Arnold Ganser, Gerard Socie, Tobias Gedde-Dahl, Edouard Forcade, Juergen Finke, Yves Chalandon, Claude-Eric Bulabois, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Nicolaus Kroeger, Igor Wolfgang Blau, Arnon Nagler, Jordi Esteve, Mohamad Mohty
Summary: Allogeneic hematopoietic cell transplantation remains the best consolidation strategy for acute myeloid leukemia with complex karyotype. AML with pure hyperdiploid karyotype may have a distinct prognosis after allo-HCT compared to non-pure hyperdiploid CK AML.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Yoshimitsu Shimomura, Sho Komukai, Tetsuhisa Kitamura, Takayoshi Tachibana, Shuhei Kurosawa, Hidehiro Itonaga, Shokichi Tsukamoto, Noriko Doki, Yuta Katayama, Ayumu Ito, Masashi Sawa, Yasunori Ueda, Hirohisa Nakamae, Yuichiro Nawa, Masatsugu Tanaka, Yasuyuki Arai, Shuichi Ota, Keisuke Kataoka, Tetsuya Nishida, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Ken Ishiyama
Summary: This study aimed to identify risk factors for patients with CK-MDS undergoing allogeneic HCT. The results showed that older age, male sex, poor comorbidity index, transfusion requirements, incomplete remission, high number of karyotype abnormalities, and monosomal karyotype were significantly associated with overall survival in CK-MDS patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Oncology
Rahul K. K. Nayak, Yi-Bin Chen
Summary: Allogeneic hematopoietic cell transplant is a central treatment for acute myeloid leukemia in first complete remission, but disease relapse remains a concern. Ongoing investigations are exploring maintenance therapies including targeted agents, hypomethylating agents, immunomodulatory therapies, and cellular therapies.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biophysics
Madlen Jentzsch, Juliane Grimm, Marius Bill, Dominic Brauer, Donata Backhaus, Karoline Goldmann, Julia Schulz, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind
Summary: Secondary or therapy-related acute myeloid leukemia (s/tAML) patients have inferior outcomes after chemotherapy and often receive allogeneic stem cell transplantation for consolidation. In the ELN favorable risk group, s/tAML patients have a higher cumulative incidence of relapse compared to de novo AML patients. However, outcomes are similar between de novo and s/tAML patients in the ELN intermediate and adverse risk group.
BONE MARROW TRANSPLANTATION
(2021)
Article
Biology
Zhenyue Wang, Ying Li, Pengchuan Sun, Mingjia Zhu, Dandan Wang, Zhiqiang Lu, Hongyin Hu, Renping Xu, Jin Zhang, Jianxiang Ma, Jianquan Liu, Yongzhi Yang
Summary: This study reveals the phylogenetic relationships and chromosomal evolution of Buxales based on high-quality genome analysis, and provides genomic resources for early-diverging eudicots.
Review
Immunology
Guancui Yang, Xiang Wang, Shiqin Huang, Ruihao Huang, Jin Wei, Xiaoqi Wang, Xi Zhang
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for myeloid malignancies, but relapse and graft-versus-host disease (GvHD) still impact patient survival. Epigenetic agents, such as hypomethylating agents (HMAs), have been explored to reduce relapse risk and prevent GvHD, and combining epigenetic therapy with HSCT may optimize the transplantation process and prevent treatment failure.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yongwoo Na, Hyunjoon Kim, Yeon Choi, Sanghee Shin, Jae Hun Jung, S. Chul Kwon, V. Narry Kim, Jong-Seo Kim
Summary: RNA-protein interaction is crucial for gene regulation post-transcription, and formaldehyde crosslinking (FAX) has been introduced as an alternative method for efficient capture of RNA-protein interactions, expanding the coverage of the study. FAX-RIC technology provided a comprehensive and unbiased RNA interactome in Xenopus laevis oocytes and embryos, revealing dynamic remodeling of RNA-protein complexes. This study demonstrates the applicability of FAX-RIC in mammalian tissue samples, extending the profiling of RNA interactome into multicellular organisms.
NUCLEIC ACIDS RESEARCH
(2021)
Article
Hematology
Jacqueline S. Garcia, Haesook T. Kim, H. Moses Murdock, Corey S. Cutler, Jennifer Brock, Mahasweta Gooptu, Vincent T. Ho, John Koreth, Sarah Nikiforow, Rizwan Romee, Roman Shapiro, Fiona Loschi, Jeremy Ryan, Geoffrey Fell, Hannah Q. Karp, Fabienne Lucas, Annette S. Kim, Danielle Potter, Thelma Mashaka, Richard M. Stone, Daniel J. DeAngelo, Anthony Letai, R. Coleman Lindsley, Robert J. Soiffer, Joseph H. Antin
Summary: This study investigated the addition of the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning chemotherapy in adult patients with high-risk AML, MDS, and MDS/MPN undergoing transplant. The results showed that this combination therapy was feasible, safe, and could potentially reduce the risk of posttransplant relapse in these patients. Further assessment of maintenance therapy after venetoclax plus FluBu2 transplant is ongoing to address relapse risk.
Article
Oncology
Jean-Francois Spinella, Jalila Chagraoui, Celine Moison, Vincent P. Lavallee, Isabel Boivin, Deanne Gracias, Sylvie Lavallee, Guillaume Richard Carpentier, Francois Beliveau, Josee Hebert, Guy Sauvageau
Summary: Monosomy 5 and deletions of the chromosome 5q (-5/del(5q)) are common chromosome abnormalities in de novo adult acute myeloid leukemia (AML) and have poor prognosis. DELE1, located in the common deleted region, was found to be the most consistently downregulated gene in -5/del(5q) AML. Partial loss of DELE1 expression reduces sensitivity to mitochondrial stress in AML cells, suggesting DELE1 haploinsufficiency may be a new driver mechanism in -5/del(5q) AML.
Article
Biochemistry & Molecular Biology
Makaia M. Papasergi-Scott, Frank E. Kwarcinski, Maiya Yu, Ouliana Panova, Ann M. Ovrutsky, Georgios Skiniotis, Gregory G. Tall
Summary: Mammalian Ric-8 proteins function as chaperones to regulate the cellular levels of heterotrimeric G protein a subunits. Ric-8A isoform interacts with Gai/o, Ga12/13, and Gaq/11 subunits, while Ric-8B acts on Gas/olf subunits. Cryo-EM structures of Ric-8B complexed with Gas and Gaolf revealed differences in isoform-specific interactions and positioning of the Ga subunit's C-terminal a5 helix within the Ric-8a-helical repeat pocket. These structures, along with thermal stability assays and cell-based folding assays, emphasize the importance of the Ga C-terminal region for binding specificity and highlight multiple structural elements contributing to Ric-8/G protein specificity.
Article
Hematology
Tomoyasu Jo, Yasuyuki Arai, Shinichiro Oshima, Tadakazu Kondo, Kaito Harada, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Masatsugu Tanaka, Yukiyasu Ozawa, Takuro Kuriyama, Kazuhiro Ikegame, Yuta Katayama, Shuichi Ota, Takahide Ara, Toshiro Kawakita, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Masamitsu Yanada
Summary: This study evaluates the impact of complex karyotype and/or monosomal karyotype in combination with various clinical factors on the outcomes of allogeneic stem cell transplantation in acute myeloid leukemia patients. The results indicate that complex karyotype and/or monosomal karyotype, age, sex, performance status, HCT-CI score, non-remission status, and time from diagnosis to transplantation independently reduce overall survival among AML patients with poor cytogenetic risk.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Maria Paola Martelli, Roberta Rossi, Alessandra Venanzi, Manja Meggendorfer, Vincenzo Maria Perriello, Giovanni Martino, Orietta Spinelli, Raffaella Ciurnelli, Emanuela Varasano, Lorenzo Brunetti, Stefano Ascani, Corinne Quadalti, Valeria Cardinali, Federica Mezzasoma, Ilaria Gionfriddo, Francesca Milano, Roberta Pacini, Alessia Tabarrini, Barbara Bigerna, Francesco Albano, Giorgina Specchia, Calogero Vetro, Francesco Di Raimondo, Ombretta Annibali, Giuseppe Avvisati, Alessandro Rambaldi, Franca Falzetti, Enrico Tiacci, Paolo Sportoletti, Torsten Haferlach, Claudia Haferlach, Brunangelo Falini
Summary: This study identified mutations in Nucleophosmin (NPM1) in acute myeloid leukemia (AML) affecting not only exon 12, but also exons 9, 11, and even exon 5. Novel rearrangements of NPM1 were also discovered. Functional studies showed the importance of cytoplasmic accumulation of NPM1 in leukemogenesis. Additional assays for molecular diagnosis of NPM1-mutated AML are needed.
Article
Biophysics
Eolia Brissot, Myriam Labopin, Frederic Baron, Ali Bazarbachi, Gesine Bug, Fabio Ciceri, Jordi Esteve, Sebastian Giebel, Maria H. Gilleece, Norbert-Claude Gorin, Francesco Lanza, Zinaida Peric, Annalisa Ruggeri, Jaime Sanz, Bipin N. Savani, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Arnon Nagler, Mohamad Mohty
BONE MARROW TRANSPLANTATION
(2021)
Article
Oncology
Eva M. Weissinger, Jochen Metzger, Michael Schleuning, Christoph Schmid, Diethelm Messinger, Gernot Beutel, Eva-Maria Wagner-Drouet, Johannes Schetelig, Herrad Baurmann, Andreas Rank, Friedrich Stolzl, Kerstin Schaefer-Eckart, Karin Westphal, Wolfgang Bethge, S. von Harsdorf, Donald W. Bunjes, Daniela Heidenreich, Stefan Klein, Ernst Holler, Hans H. Kreipe, Danny Jonigk, Irina Tueruechanow, Julia Raad, Armin Papkalla, Heiko von der Leyen, Lothar Hambach, Iyas Hamwi, Steve Ehrlich, Jurgen Krauter, Michael Stadler, Arnold Ganser
Summary: The study investigated the effectiveness of preemptive prednisolone treatment in patients with acute graft-versus-host disease, and the results showed no significant difference in the incidence or severity of acute GvHD, and did not increase the relapse rate.
Article
Hematology
Esther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, Gesine Bug, Martina Crysandt, Sabine Dressler, Andreas Hausmann, Daniela Heidenreich, Klaus Hirschbuehl, Matthias Hoepting, Edgar Jost, Jennifer Kaivers, Stefan Klein, Michael Koldehoff, Lambros Kordelas, Oliver Kriege, Lutz P. Mueller, Christina Rautenberg, Judith Schaffrath, Christoph Schmid, Daniel Wolff, Rainer Haas, Martin Bornhaeuser, Thomas Schroeder, Guido Kobbe
Summary: The retrospective study evaluated the efficacy of Venetoclax combined with hypomethylating agents in treating relapse of myeloid malignancies after alloHSCT. Results showed significant risk of neutropenia and infections, with substantial toxicity. Patients who received the treatment as first salvage therapy or for molecular relapse derived the greatest benefit.
ANNALS OF HEMATOLOGY
(2021)
Article
Biophysics
Klaus Hirschbuehl, Myriam Labopin, Mohamed Houhou, Ludovic Gabellier, Helene Labussiere-Wallet, Bruno Lioure, Dietrich Beelen, Jan Cornelissen, Gerald Wulf, Pavel Jindra, Herve Tilly, Jakob Passweg, Riita Niittyvuopio, Gesine Bug, Christoph Schmid, Arnon Nagler, Sebastian Giebel, Mohamad Mohty
Summary: The study evaluated the efficacy of second- and third-generation TKI in 140 patients with Ph + ALL, showing a response rate of 71% and an overall survival rate of 49% at 2 years and 33% at 5 years. TKI were found to be important compounds for managing active Ph + ALL post alloSCT, with comparable toxicity to pretransplant use.
BONE MARROW TRANSPLANTATION
(2021)
Review
Oncology
Christoph Schmid, Juergen Kuball, Gesine Bug
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Nutrition & Dietetics
R. Toenges, H. Greinix, A. Lawitschka, J. Halter, A. Baumgartner, A. Simon, J. Arends, P. Jaeger, M. Middeke, I. Hilgendorf, S. Klein, E. M. Wagner-Drouet, C. Schmid, G. Bug, D. Wolff
Summary: The study investigates the clinical practice of nutritional treatment after alloHSCT, revealing variability in nutritional approaches and indicating a need for more high-quality data to support evidence-based nutrition for patients.
CLINICAL NUTRITION
(2021)
Article
Oncology
Jordi Esteve, Sebastian Giebel, Myriam Labopin, Tomasz Czerw, Depei Wu, Liisa Volin, Gerard Socie, Ibrahim Yakoub-Agha, Johan Maertens, Jan J. Cornelissen, Arnaud Pigneux, Avichai Shimoni, Rainer Schwerdtfeger, Helene Labussiere-Wallet, Nigel Russell, Anton Schattenberg, Patrice Chevallier, Vladimir Koza, Robin Foa, Christoph Schmid, Zinaida Peric, Mohamad Mohty, Arnon Nagler
Summary: This study analyzed the outcomes of patients with t(4;11) BCP-ALL treated with alloHSCT, finding that a negative MRD status pre-transplant was the strongest beneficial factor. Patients with t(4;11) BCP-ALL had inferior outcomes compared to those with NK BCP-ALL when MRD was detectable.
Editorial Material
Hematology
Christoph Schmid
Summary: The study reported successful generation and safe clinical application of mLSTs derived from healthy stem cell donors, showing low incidence of GVHD after transfusion of mLSTs and long-term remission and clinical responses in patients.
Article
Biophysics
Mohamed A. Kharfan-Dabaja, Myriam Labopin, Ali Bazarbachi, Fabio Ciceri, Juergen Finke, Benedetto Bruno, Martin Bornhaeuser, Tobias Gedde-Dahl, Helene Labussiere-Wallet, Riitta Niittyvuopio, Thomas Valerius, Emanuele Angelucci, Arne Brecht, Dolores Caballero, Juergen Kuball, Victoria Potter, Christoph Schmid, Johanna Tischer, Tsila Zuckerman, Fabio Benedetti, Didier Blaise, Jose Luis Diez-Martin, Jaime Sanz, Annalisa Ruggeri, Eolia Brissot, Bipin N. Savani, Sebastian Giebel, Arnon Nagler, Mohamad Mohty
Summary: The optimal donor choice for a second allo-HCT in relapsed acute lymphoblastic leukemia remains unclear. Comparing outcomes between using HLA-matched unrelated donors (MUD) and haploidentical donors shows no major difference in overall survival for ALL patients needing a second allo-HCT. Peripheral blood stem cells are the most common cell source, with a higher proportion of bone marrow cells used in the haploidentical group.
BONE MARROW TRANSPLANTATION
(2021)
Article
Immunology
M. Merle, D. Fischbacher, A. Liepert, C. Grabrucker, T. Kroell, A. Kremser, J. Dreyssig, M. Freudenreich, F. Schuster, A. Borkhardt, D. Kraemer, C-H Koehne, H. J. Kolb, C. Schmid, H. M. Schmetzer
Summary: This study demonstrated that the release of chemokines plays a role in the antileukemic T-cell activity, suggesting potential immune-modifying strategies to enhance immune responses against leukemia.
Article
Biophysics
Johanna Waidhauser, Myriam Labopin, Jordi Esteve, Nicolaus Kroger, Jan Cornelissen, Tobias Gedde-Dahl, Gwendolyn Van Gorkom, Jurgen Finke, Montserrat Rovira, Nicolaas Schaap, Eefke Petersen, Dietrich Beelen, Donald Bunjes, Bipin Savani, Christoph Schmid, Arnon Nagler, Mohamad Mohty
Summary: This study analyzed the prognostic value of RUNX1 mutation in acute myeloid leukemia patients after allogeneic stem cell transplantation, and found that in the first complete remission, the presence of RUNX1 mutation did not significantly impact survival rates.
BONE MARROW TRANSPLANTATION
(2021)
Article
Biophysics
Christoph Schmid, Myriam Labopin, Nicolaas Schaap, Hendrik Veelken, Arne Brecht, Michael Stadler, Juergen Finke, Frederic Baron, Matthew Collin, Gesine Bug, Per Ljungman, Didier Blaise, Johanna Tischer, Adrian Bloor, Aleksander Kulagin, Sebastian Giebel, Norbert-Claude Gorin, Jordi Esteve, Fabio Ciceri, Bipin Savani, Arnon Nagler, Mohamad Mohty
Summary: This study analyzed 318 acute leukemia patients who received DLI after alloSCT, showing that preemptive DLI was effective in reducing MRD and increasing chimerism, thus improving survival rates for patients.
BONE MARROW TRANSPLANTATION
(2022)
Article
Oncology
Peter-Martin Bruch, Sascha Dietrich, Herve Finel, Ariane Boumendil, Hildegard Greinix, Thomas Heinicke, Wolfgang Bethge, Dietrich Beelen, Christoph Schmid, Hans Martin, Luca Castagna, Christof Scheid, Kerstin Schaefer-Eckart, Joerg Bittenbring, Juergen Finke, Henrik Sengeloev, Mael Heiblig, Jan Cornelissen, Patrice Chevallier, Mohamad Mohty, Stephen Robinson, Silvia Montoto, Peter Dreger
Summary: This retrospective study analyzed the outcomes of 162 adult patients with BPDCN who underwent a first HCT. The study found that MAC (especially TBI-based) significantly improved the prognosis of alloHCT recipients, and autoHCT could be considered for patients who are not eligible for MAC.
Article
Hematology
Andreas Rank, Christophe Peczynski, Myriam Labopin, Matthias Stelljes, Celestine Simand, Grzegorz Helbig, Jurgen Finke, Stella Santarone, Johanna Tischer, Andrzej Lange, Martin Mistrik, Mohamed Houhou, Christoph Schmid, Arnon Nagler, Mohamad Mohty
Summary: This retrospective analysis evaluated 45 patients with acute myeloid or lymphoblastic leukemia who received a third allogeneic stem cell transplantation (alloSCT3). After the third transplantation, 38 patients engrafted and 26 achieved remission, but the overall survival and progression-free survival rates at 1 year were low, indicating poor outcomes. Factors that may improve patient outcomes include donor changes, selection of an unrelated donor for alloSCT3, and transplantation in more recent years.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Hematology
Roni Shouval, Joshua A. Fein, Myriam Labopin, Christina Cho, Ali Bazarbachi, Frederic Baron, Gesine Bug, Fabio Ciceri, Selim Corbacioglu, Jacques-Emmanuel Galimard, Sebastian Glebel, Maria H. Gilleece, Sergio Giralt, Ann Jakubowski, Silvia Montoto, Richard J. O'Reilly, Esperanza B. Papadopoulos, Zinaida Peric, Annalisa Ruggeri, Jaime Sanz, Craig S. Sauter, Bipin N. Savani, Christoph Schmid, Alexandros Spyridonidis, Roni Tamari, Jurjen Versluis, Ibrahim Yakoub-Agha, Miguel Angel Perales, Mohamad Mohty, Arnon Nagler
Summary: The study developed a contemporary disease-risk stratification system that categorized patients into five risk groups based on histology and remission status. The system was able to predict overall survival after allogeneic hematopoietic stem-cell transplantation and may serve as a benchmark for future studies on heterogeneous cohorts.
LANCET HAEMATOLOGY
(2021)